Related Experiment Video
Updated: Jul 11, 2026

07:12
Design of a Cyclic Pressure Bioreactor for the Ex Vivo Study of Aortic Heart Valves
Published on: August 23, 2011
16.4K
Discovering and Developing Successful Cardiovascular Therapeutics: A Conversation With James N. Topper, MD, PhD
Circulation
|November 25, 2016
Summary
Dr. James N. Topper is a Managing General Partner at Frazier Healthcare Partners, leading life science venture investments. He has over 25 years of experience building successful therapeutics companies.
Area of Science:
- Biophysics and Medicine
- Venture Capital and Life Sciences
Background:
- Dr. James N. Topper, MD, PhD, is a Managing General Partner at Frazier Healthcare Partners, directing the Life Science Venture practice.
- He possesses over 25 years of experience in founding and developing successful therapeutics-focused companies.
Discussion:
- Recognized as a leading venture capitalist on the Midas List in 2011 and 2016.
- Acknowledged by Forbes in 2013 as a top 10 healthcare investor.
Key Insights:
- Extensive experience in entrepreneurship and company building within the therapeutics sector.
- Strong foundation in biophysics, medicine, internal medicine, and cardiovascular disease.
Outlook:
- Continued leadership in life science venture capital, driving innovation in therapeutics.
- Leveraging deep scientific and investment expertise to foster groundbreaking healthcare companies.
Related Concept Videos
Cardiovascular Drugs: Classification based on Therapeutic Indications
Cardiovascular diseases, encompassing a range of conditions, can significantly affect the heart's operations and the overall circulatory system. These conditions impair the heart's ability to pump blood, leading to a deficit in oxygen supply to crucial organs. Anomalies in the heart's electrical system, known as arrhythmias, can cause heartbeats to accelerate or slow down. Usually, heart rates increase during physical activity and decrease while resting or sleeping. However, frequent irregular...
Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure
Oxygen therapy has emerged as a significant tool in enhancing the quality of life for patients suffering from pulmonary arterial hypertension (PAH). While this therapy has principally been studied on patients with significant hypoxemia, this therapeutic approach helps prevent potential organ damage and can be administered in the comfort of one's home.
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue, improving...
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue, improving...
Heart Failure V: Medical Management
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Heart Failure VI: Adjunct Therapies
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
Hypertension IV: Drug Therapy and Lifestyle Modifications
Multiple classes of antihypertensive medications are employed in treating hypertension. The most commonly recommended first-line treatments include:Thiazide Diuretics, such as chlorthalidone, increase sodium and water excretion from the body, reducing blood volume and blood pressure.Angiotensin-converting enzyme inhibitors, like lisinopril, block the conversion of angiotensin I to II, a potent vasoconstrictor lowering blood pressure.Angiotensin II Receptor Blockers (ARBs) prevent angiotensin II...
Atherosclerosis III: Management
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...

